NYSE$ALUR
Allurion Technologies Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Allurion Technologies Inc reported its Q1 2026 financial results with lower revenue and increased net loss.
Allurion Technologies Inc reported revenue of $2.9 million for the first quarter of 2026, down from $5.6 million in the prior year period. The company recorded a net loss of $6.1 million and a loss from operations of $3.7 million. Cash and cash equivalents stood at $5.1 million with total assets of $14.0 million as of March 31, 2026.
- Revenue declined 47% year-over-year to $2.9 million due to reduced sales and marketing investment and distributor transitions.
- Gross profit fell to $1.2 million with gross margin pressure from higher inventory provisions.
- Net loss widened to $6.1 million amid lower operating expenses but significant non-cash warrant and debt fair value adjustments.
- The company received FDA approval for its Allurion Gastric Balloon System in February 2026 and completed a warrant inducement raising $3.1 million.
Headline financials
Revenue & EPS history
Allurion · Revenue · Quarterly
$2.95M
Forward guidance
The company expects to continue incurring operating losses while focusing on regulatory approvals, product commercialization, and cost management.
Tailwinds
- FDA approval received for Allurion Gastric Balloon System in February 2026
- Completed warrant inducement transaction generating $3.1 million in gross proceeds
Headwinds
- Substantial doubt about ability to continue as a going concern
- Non-compliance with financial covenants under credit facilities
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+1.5%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-6.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+47.1%
Q4 2025
Best reaction
-43.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.0% | +25.1% | — | |
| Q4 2025 | +47.1% | +35.3% | +47.1% | |
| Q3 2025 | +1.4% | -6.0% | +12.1% | |
| Q2 2025 | +0.8% | -8.1% | -16.3% | |
| Q1 2025 | +25.1% | +29.7% | +5.1% | |
| Q4 2024 | +0.3% | +3.2% | -22.8% | |
| Q3 2024 | -43.7% | -46.2% | -51.3% | |
| Q2 2024 | -12.7% | -17.0% | -20.8% | |
| Q1 2024 | -1.0% | -8.8% | -28.4% | |
| Q4 2023 | -11.9% | -11.0% | -5.2% | |
| Q3 2022 | +2.4% | +0.7% | -18.7% | |
| Q3 2023 | +6.7% | +2.4% | -15.9% | |
| Q4 2022 | -2.3% | +3.8% | -3.6% | |
| Q2 2022 | -2.3% | +3.8% | -3.6% | |
| Q1 2023 | -2.3% | +3.8% | -3.6% | |
| Q2 2023 | -2.3% | +3.8% | -3.6% | |
| Q1 2022 | +0.0% | +0.2% | +0.3% | |
| Q4 2021 | +0.1% | +0.3% | -0.1% | |
| Q3 2021 | -0.2% | +0.0% | +0.0% | |
| Q2 2021 | -0.1% | -0.5% | -1.3% | |
| Q1 2021 | +0.9% | +1.0% | +2.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro